Merck
Last updated Jun 17, 2026
Evidence Sources
13
Competitive Findings
7
Portfolio Developments
18
Regulatory Precedents
8
Clinical Programs
8
Confidence Coverage
67%
Audit
- Competitor findings: 7
- Portfolio developments: 18
- Self-competition findings removed: 20
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Immune Checkpoint Inhibitor
- Small Molecule
- ALK Inhibitor
- Non-Small Cell Lung Cancer
Highest priority development: Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Portfolio development
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer is an owned Merck portfolio development in Oncology · NSCLC.
Competitive pressure: High
Portfolio impact: High
Evidence coverage: 67%
Active Signals
67
Investigate Priority
20
Opportunity Score
17131
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- EscalateJun 17, 2026Score 267Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV)
- InvestigateJun 16, 2026Score 262Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
- InvestigateJun 16, 2026Score 262Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
Related Assets
Portfolio asset pages with evidence-based assessments.
- ALECENSAModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsClinicalTrials.govPortfolio
- Low Confidence · 0%Sources (3)MerckClinicalTrials.govPortfolio
- Low Confidence · 0%Sources (3)Humanexa SignalsFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell LungModerate Confidence · 68%
Elevated competitive pressure
Sources (2)MerckCompetitiva - European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonModerate Confidence · 77%
Elevated competitive pressure
Sources (2)MerckCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinomaHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — KEYTRUDA QLEX (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — KEYTRUDA (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — WELIREG (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- ALECENSAModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov - FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell LungModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- EscalateScore 267Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV)
- InvestigateScore 262Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
- InvestigateScore 262Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
- EscalateScore 260Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Merck right now?
- Which regulatory precedents should Merck monitor in Oncology and Immune Checkpoint Inhibitor?
- How does FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an… compare to the nearest competitive programs?
- What signals require immediate investigation for Merck?
- Summarize the strategic implications of recent developments for Merck.
- Where is the greatest uncertainty in Merck's competitive positioning?